Clinical Trial Update: Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 trial of pembrolizumab in PD-L1–expressing Diffuse Large B-Cell Lymphoma was terminated, and results were posted on February 20, 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Diffuse Large B Cell Lymphoma, Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-20